Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OCU-10-C-110 in nAMD
NCT05904691Phase 1Active, not recruiting
- Sponsor
- Ocugenix
- Start
- Nov 2023
- Primary completion
- Nov 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of OCU-10-C-110 in neovascular age-related macular degeneration (NVAMD) (2 cohorts), sponsored by Ocugenix. Primary endpoint: Ocular Adverse Events at 12 weeks. Started Nov 2023; status: active, not recruiting.
02
Drugs
OCU-10-C-110
03
Conditions
neovascular age-related macular degeneration (NVAMD)
Beyond the preview
Go deeper on NCT05904691.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05904691.